AbstractThe relevance of non‐pharmacological cognitive stimulation treatments in patients with MCI and AD is increasingly recognized as tools for slowing the progression of the disease and preserving autonomy. However, the registration and quantification of the impact is diffcult to consign.The objective of the present work is to present the case of a 59 year old woman, with early onset AD who is undergoing cognitive stimulation treatment and its evolution in cognitive and functional performance.Initially he presented with typical subjective memory complaint, he obtained a score of 25/30 in MMSE and a CDR of 1. An 18F‐FDG study was performed that showed the typical hypometabolism pattern and a positive 11C‐PIB PET/CT for cortical amyloid deposits. On functionality scales, he scored 100 on the Barthel index and 8 on the Lawton and Brody scale. He underwent cognitive stimulation treatment, from that moment and uninterruptedly, through biweekly sessions of 45‐60 minutes each. It currently has a CDR of 2 and an MMSE of 15/30. In relation to its functionality, it presents a Barthel Index of 100/100 and a Lawton and Brody scale of 4/8.Although the inevitable progression of the disease has an evident impact on cognitive functions, which is clearly reflected in the neuropsychological tests, the functionality of the patient has been fully maintained for basic activities of daily living, and partially for activities instrumentals. This demonstrates the relevance of personalized cognitive stimulation treatments in patients with Alzheimer’s disease, especially in forms of early presentation, when the disease is more aggressive and when patients are very active at the time of diagnosis.